FDA Approves Next-Generation Possis Medical, Inc. AngioJet(R) System
MINNEAPOLIS--(BUSINESS WIRE)--Possis Medical, Inc. (NASDAQ:POSS) a developer, manufacturer and marketer of pioneering medical devices for the cardiovascular and vascular treatment markets, today announced that it has received marketing approval from the U.S. Food and Drug Administration (FDA) for its new AngioJet® Ultra Thrombectomy System. Ultra is the next-generation, completely re-engineered version of Possis’ proven, industry leading AngioJet Rheolytic™ Thrombectomy System. AngioJet is marketed for blood clot removal (thrombectomy) from arterial and venous blood vessels. The new Ultra System features a simple and fast setup process, the flexibility to use a broad range of catheters, a sleeker design, lighter weight, and handling improvements that make it significantly easier to maneuver than the previous AngioJet drive unit.